In this episode I will be discussing CagriSema, an investigational combination therapy expected to launch between late 2026 and early 2027. The treatment combines semaglutide and cagrilintide, targeting complementary mechanisms that regulate appetite and satiety.
Clinical trial data indicate weight reduction of up to 22.7%, suggesting improved efficacy relative to existing monotherapies.
The development reflects a broader shift toward combination-based treatment models, consistent with approaches used in managing chronic conditions such as diabetes and hypertension.
Listen to the episode for a closer look at what this could mean for treatment pathways and patient outcomes.